Nomura Asset Management CO LTD Viridian Therapeutics, Inc.\De Transaction History

Nomura Asset Management CO LTD

  • $31.8 Billion
  • Q3 2024
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$12.16 - $23.33 $0 - $0
0 New
0 $0
Q2 2024

Aug 14, 2024
BUY
$11.6 - $17.26 $0 - $0
0 New
0 $0
Q1 2024

May 13, 2024
BUY
$17.09 - $23.82 $0 - $0
0 New
0 $0
Q4 2023

Feb 09, 2024
BUY
$11.12 - $22.5 $0 - $0
0 New
0 $0
Q3 2023

Nov 03, 2023
BUY
$15.16 - $24.7 $0 - $0
0 New
0 $0
Q2 2023

Aug 14, 2023
BUY
$22.57 - $29.67 $0 - $0
0 New
0 $0
Q1 2023

May 11, 2023
BUY
$25.04 - $37.6 $0 - $0
0 New
0 $0

Others Institutions Holding VRDN

# of Institutions
179
Shares Held
76.8M
Call Options Held
581K
Put Options Held
439K
View Full List

About Viridian Therapeutics, Inc.\DE

VRDN Quotes by TradingView
  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $830M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email